That might have not passed through FTC. Remember $CELG holds scores of license agreements that gave it a call option on virtually every idea in oncology, including XLRN. So they were already benefitting from any upside upon success. At the time in mid 2010's $CELG was way behind in CAR-T, which held great promise (also the premise of $BMY deal to buy $CELG). With Juno $CELG had 5 late stage CAR-T drugs, 2 near completion and holds all the upside with $XLRN. Think about the risk they would have taken ($XLRN was at a premium then as compared to Juno) especially in summer when $XLRN muscular dystrophy drug (supposed to be a big money generator) failed. I think with this merger of $BMY and $CELG they have a potentially one of the best pipelines (considering all the funky, and manifold licensing deals of $CELG).